Chugai Obtains Regulatory Approval for Lunsumio and Polivy Combination Therapy for Additional Indication of Relapsed or Refractory Large B-cell Lymphoma
A new treatment option that has demonstrated a high response rate and suppression of disease progres...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
A new treatment option that has demonstrated a high response rate and suppression of disease progres...
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Press releaseMar 27, 2026Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated…
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven...
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic ob...
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact area...
2026 03 27 12 00 00 3263711
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU appr...